PCSK7 and metabolic dysfunction-associated steatotic liver disease: Since PC7 is implicated in liver diseases and hepatic cancer, our results suggest that these miRNAs could modulate PCSK7 expression in different liver diseases, likely being protective against the development of MAFLD/NAFLD [16], where PC7 seems to play a non-enzymatic role [13,17], possibly as a chaperone for some lipoproteins such as apolipoprotein B (Vatsal S. et al., in preparation).